In Brief: Chinese ephedra regs
This article was originally published in The Tan Sheet
Executive Summary
Chinese ephedra regs: China does not permit ephedra as a single component in traditional medicine preparations, Mei-Ling Hsiao, director of the China Health Department's Bureau of Pharmaceutical Affairs, tells FDA in an Aug. 23 letter. Hsiao also notes that products containing the herb may not be sold as dietary supplements and may not contain over 15 mg of the substance. In similar letters, Japan, Britain, Sweden, Australia, and the Ukraine all informed FDA that ephedra-containing products must be sold as drugs in their respective countries. FDA had asked for information on the "regulation/approval/registration" status of the herb in a number of countries...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning